PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:PHN - IT0005274094 - Common Stock
63.9 EUR
-1.1 (-1.69%)
Taking everything into account, PHN scores 7 out of 10 in our fundamental rating. PHN was compared to 13 industry peers in the Personal Care Products industry. Both the health and profitability get an excellent rating, making PHN a very profitable company, without any liquidiy or solvency issues. While showing a medium growth rate, PHN is valued expensive at the moment. These ratings would make PHN suitable for quality investing!
1. Profitability
1.1 Basic Checks
- In the past year PHN was profitable.
- In the past year PHN had a positive cash flow from operations.
- Each year in the past 5 years PHN has been profitable.
- Each year in the past 5 years PHN had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 20.17%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- PHN has a better Return On Equity (36.55%) than 100.00% of its industry peers.
- PHN's Return On Invested Capital of 25.72% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PHN is significantly above the industry average of 11.91%.
- The last Return On Invested Capital (25.72%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.17% | ||
| ROE | 36.55% | ||
| ROIC | 25.72% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
1.3 Margins
- The Profit Margin of PHN (13.39%) is better than 76.92% of its industry peers.
- PHN's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 21.79%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- PHN's Operating Margin has been stable in the last couple of years.
- Looking at the Gross Margin, with a value of 97.13%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.79% | ||
| PM (TTM) | 13.39% | ||
| GM | 97.13% |
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
- PHN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- PHN has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 5 years ago, PHN has less shares outstanding
- Compared to 1 year ago, PHN has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 10.81 indicates that PHN is not in any danger for bankruptcy at the moment.
- PHN's Altman-Z score of 10.81 is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
- PHN has a debt to FCF ratio of 2.01. This is a good value and a sign of high solvency as PHN would need 2.01 years to pay back of all of its debts.
- PHN has a better Debt to FCF ratio (2.01) than 69.23% of its industry peers.
- A Debt/Equity ratio of 0.24 indicates that PHN is not too dependend on debt financing.
- The Debt to Equity ratio of PHN (0.24) is better than 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 2.01 | ||
| Altman-Z | 10.81 |
ROIC/WACC3.22
WACC7.98%
2.3 Liquidity
- A Current Ratio of 2.19 indicates that PHN has no problem at all paying its short term obligations.
- The Current ratio of PHN (2.19) is better than 92.31% of its industry peers.
- PHN has a Quick Ratio of 1.86. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of PHN (1.86) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.19 | ||
| Quick Ratio | 1.86 |
3. Growth
3.1 Past
- PHN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.84%, which is quite good.
- The Earnings Per Share has been growing by 14.63% on average over the past years. This is quite good.
- PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.35%.
- The Revenue has been growing by 16.59% on average over the past years. This is quite good.
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%
3.2 Future
- The Earnings Per Share is expected to grow by 15.13% on average over the next years. This is quite good.
- PHN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.74% yearly.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 25.46, PHN can be considered very expensive at the moment.
- The rest of the industry has a similar Price/Earnings ratio as PHN.
- When comparing the Price/Earnings ratio of PHN to the average of the S&P500 Index (28.82), we can say PHN is valued inline with the index average.
- A Price/Forward Earnings ratio of 26.17 indicates a quite expensive valuation of PHN.
- 61.54% of the companies in the same industry are cheaper than PHN, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.95, PHN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.46 | ||
| Fwd PE | 26.17 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit more expensive than 69.23% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 76.92% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.34 | ||
| EV/EBITDA | 14.48 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHN does not grow enough to justify the current Price/Earnings ratio.
- PHN has an outstanding profitability rating, which may justify a higher PE ratio.
- PHN's earnings are expected to grow with 15.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.07
PEG (5Y)1.74
EPS Next 2Y13.31%
EPS Next 3Y15.13%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.52%, PHN has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 2.23, PHN is paying slightly less dividend.
- Compared to an average S&P500 Dividend Yield of 1.82, PHN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.52% |
5.2 History
- On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 39.70% of the earnings are spent on dividend by PHN. This is a low number and sustainable payout ratio.
- PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.7%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
PHARMANUTRA SPA / PHN.MI FAQ
What is the fundamental rating for PHN stock?
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.
Can you provide the valuation status for PHARMANUTRA SPA?
ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.
What is the profitability of PHN stock?
PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.
How financially healthy is PHARMANUTRA SPA?
The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.
Is the dividend of PHARMANUTRA SPA sustainable?
The dividend rating of PHARMANUTRA SPA (PHN.MI) is 5 / 10 and the dividend payout ratio is 39.7%.